CRM Home | Insightmedhub India Portal
Committed to Health Beyond Today
Improving life of patients with cardio-renal-metabolic disease for more than 140 years.
Explore our original research product journey
Innovation in care
Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.
Holistic Cardio-Renal-Metabolic care
CVD Burden in India
Ischaemic heart disease and stroke vary across India, requiring urgent health action.6
CRM risk in India
3 out of 5 newly diagnosed T2DM cases at very high CVD risk.2
Burden of CKD in India
Kidney disease significantly contributes to global morbidity and mortality.3
Integrated management across interconnected risks
Why it matters:
- The burden of cardiovascular disease and CKD remains high in T2DM patients
- Delayed recognition of interconnected risks can lead to increased complications and mortality
- Early, integrated intervention across CV, renal, and metabolic domains is essential
- A holistic strategy enables better risk reduction and long-term patient outcomes
Original research product
Bioequivalence and therapeutic equivalence are not similar8,9
Latest insights & updates
Can you conquer the Glyxambi Octet A1c League?
Navigate diabetes management challenges, score points with every correct decision, and progress through the league as you work towards championship status.
JARDIANCE®: A 4-time Prix-Galien award winner recognised for scientific innovation and impact on human health18
(Prix-Galien is regarded as Noble prize in pharmaceutical research and development)
Explore the Prix Galien journey
References
Anjana RM, Unnikrishnan R, Mugilan P, et al. Causes and predictors of mortality in Asian Indians with and without diabetes-10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES - 150). PLoS One. 2018;13(7):e0197376.
Unnikrishnan AG, Sahay RK, Phadke U, et al. Cardiovascular risk in newly diagnosed type 2 diabetes patients in India. PLoS One. 2022;17(3):e0263619.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.
Roy V, Rana P. Prescribing generics: All in a name. Indian J Med Res. 2018;147(5):442-444.
Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304-312.